• Pembrolizumab regimen extends OS in metastatic gastric, gastroesophageal junction cancers

    9 days ago - By Healio

    The addition of pembrolizumab to chemotherapy improved OS among certain patients with gastric or gastroesophageal junction cancers, according to the agent's manufacturer.
    Pembrolizumab is an anti-PD-1 therapy.
    The randomized phase 3 KEYNOTE-859 trial evaluated the efficacy of chemotherapy plus pembrolizumab or placebo as first-line treatment for patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal adenocarcinoma.
    Researchers randomly assigned 1,579 patients to fluoropyrimidine- and platinum-containing chemotherapy plus either
    Read more ...